PR Newswire (Mon, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,342 people get SGMO articles and Market Currents by email alert.
Get email alerts on SGMO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 8, 2013)
-
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
-
-
-
-
PR Newswire (Mar 5, 2013)
-
PR Newswire (Feb 27, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Progenics Pharmaceuticals JumpedM. E. Garza • Thu, Dec 1, 2011 -
-
11 Biotech Stocks With Bullish Short TrendsKapitall • Wed, Nov 23, 2011
-
20 Biotech Stocks With Strong Corporate GovernanceKapitall • Wed, Oct 5, 2011
-
-
-
-
Squeeze Ideas: 17 Short Seller Targets for a WatchlistKapitall • Fri, Apr 1, 2011
-
Sangamo's CEO Discusses Q1 2012 Results - Earnings Call TranscriptWed, May 2, 2012
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
at CNBC.com (Apr 3, 2013)
-
PR Newswire (Mar 5, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Jan 2, 2013)
-
PR Newswire (Nov 27, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 24, 2012)
SGMO vs. ETF Alternatives
Company Description
We, and our licensed partners, are the leaders in the research, development and commercialization of zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins, and have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can be engineered... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 20, 11:04 AM Sangamo BioSciences (SGMO -4.5%) takes a bit of a hit this morning, despite the presentation of new data demonstrating the successful application of its In Vivo Protein Replacement Platform in a mouse model. The company, in partnership with Shire (SHPG +1.8%), is developing ZFP Therapeutics for both hemophilia A and B using this approach. The data was presented late last week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City. 3 Comments [Healthcare, On the Move]
- Wednesday, May 15, 12:48 PM Sangamo BioSciences (SGMO -3.7%) stabilizes after a volatile opening this morning, albeit lower, after announcing the presentation of encouraging new clinical data from its program to develop a ZFP Therapeutic for HIV/AIDS. The data, which demonstrates that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, is being presented at the 16th Annual Meeting of the American Society of Gene and Cell Therapy. 2 Comments [Healthcare, On the Move]
- Wednesday, May 8, 4:05 PM Sangamo BioSci (SGMO): Q1 EPS of -$0.13 beats by $0.04. Revenue of $4.6M beats by $0.81M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 8, 12:10 AM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
- Tuesday, May 7, 5:35 PM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
- Wednesday, March 6, 3:42 PM Sangamo BioSciences (SGMO -8.3%) slides after presenting new data from its program to develop a functional cure for HIV/AIDS in two presentations at the 20th Conference on Retroviruses and Opportunistic Infections. SGMO expects to present preliminary data in the first half of 2013 and the full data set from both trials by the end of 2013. 1 Comment [Healthcare, On the Move]
- Thursday, February 28, 12:12 PM Sangamo Biosciences (SGMO +9.4%) pops again today after being initiated by Lazard with a Buy rating and a target price of $16 a share. The stock's been on fire the couple sessions on no significant news, having risen 18% since Tuesday. Worth noting: the stock has a short ratio of 9.1 and short interest of 6.1M shares at present, versus an average of around 3.15 for its sector. Comment! [Healthcare, On the Move]
-
Thursday, February 7, 1:05 PM
Midday top 10 gainers: SUTR +40%. FMFC +39%. OXGN +23%. VSAT +22%. TRLG +20%. GEOS +20%. DV +18%. ARKR +17%. PLNR +16%. SCKT +15%.
Midday top 10 losers: AKAM -16%. ADEP -16%. EPAX -15%. OSUR -14%. SGMO -14%. IRBT -13%. ATML -13%. BONT -13%. RTIX -13%. PSMI -12%. Comment! [On the Move] - Wednesday, February 6, 5:14 PM More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were generated from the Company's collaboration agreements with Shire (SHPG), Dow AgroSciences (DAS) and Sigma-Aldrich Corporation (SIAL), plus additional research grants. The company guides FY2013 revenue slightly to the lower side of estimates, now expecting to earn between $20M -24M, versus the consensus of $23.09M. Shares -1% AH. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, February 6, 12:10 AM Notable earnings after Wednesday’s close: AKAM, ALL, ARAY, ARRS, ATML, ATO, BDN, CBG, CINF, CVA, CYS, DV, ENS, FMC, GHDX, GMCR, HIMX, IACI, IRBT, LF, NTES, NWSA, ORLY, OSUR, PAA, PDH, PNG, PRU, QUIK, SGMO, SRCL, TQNT, TRLA, TRLG, TSO, TWO, V, XIDE, YELP Comment! [Earnings]
- Tuesday, February 5, 5:35 PM Notable earnings after Wednesday’s close: AKAM, ALL, ARAY, ARRS, ATML, ATO, BDN, CBG, CINF, CVA, CYS, DV, ENS, FMC, GHDX, GMCR, HIMX, IACI, IRBT, LF, NTES, NWSA, ORLY, OSUR, PAA, PDH, PNG, PRU, QUIK, SGMO, SRCL, TQNT, TRLA, TRLG, TSO, TWO, V, XIDE, YELP 1 Comment [Earnings]
- Monday, January 28, 3:01 PM Shares of Sangamo Biosciences (SGMO -0.9%) slip after SEC filings show the company's CEO and CFO both sold shares of the company. 1 Comment [Healthcare]
- Wednesday, October 24, 2012, 4:32 PM Sangamo BioSciences (SGMO): Q3 EPS of -$0.11 beats by $0.03. Revenue of $4.9M beats by $1.2M. Shares -0.5% AH. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 24, 2012, 12:10 AM Notable earnings after Wednesday’s close: AB, ACOM, AEM, AKAM, AMP, CCI, CDNS, CLF, CMO, CROX, CTXS, EGHT, ENTR, EQR, FFIV, FIO, IDCC, INFN, KBR, LOGI, LSI, OI, ORLY, RRC, RYL, SGMO, SIMO, SPN, SRCL, SYMC, SYNC, TAL, TER, TEX, TLAB, TQNT, TRN, TSCO, TWI, WLL, WYNN, XNPT, ZNGA Comment! [Earnings]
- Tuesday, October 23, 2012, 5:35 PM Notable earnings after Wednesday’s close: AB, ACOM, AEM, AKAM, AMP, CCI, CDNS, CLF, CMO, CROX, CTXS, EGHT, ENTR, EQR, FFIV, FIO, IDCC, INFN, KBR, LOGI, LSI, OI, ORLY, RRC, RYL, SGMO, SIMO, SPN, SRCL, SYMC, SYNC, TAL, TER, TEX, TLAB, TQNT, TRN, TSCO, TWI, WLL, WYNN, XNPT, ZNGA Comment! [Earnings]
- Wednesday, July 25, 2012, 6:40 PM Sangamo BioSci (SGMO): Q2 EPS of -$0.11 beats by $0.04. Revenue of $4.6M (+207% Y/Y) beats by $0.95M. Shares +0.4% AH. (PR) Comment! [Earnings, Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.